The biology and treatment of oligometastatic cancer

Diane K. Reyes, Kenneth Pienta

Research output: Contribution to journalArticle

Abstract

Clinical reports of limited and treatable cancer metastases, a disease state that exists in a transitional zone between localized and widespread systemic disease, were noted on occasion historically and are now termed oligometastasis. The ramification of a diagnosis of oligometastasis is a change in treatment paradigm, i.e. if the primary cancer site (if still present) is controlled, or resected, and the metastatic sites are ablated (surgically or with radiation), a prolonged disease-free interval, and perhaps even cure, may be achieved. Contemporary molecular diagnostics are edging closer to being able to determine where an individual metastatic deposit is within the continuum of malignancy. Preclinical models are on the outset of laying the groundwork for understanding the oligometastatic state. Meanwhile, in the clinic, patients are increasingly being designated as having oligometastatic disease and being treated owing to improved diagnostic imaging, novel treatment options with the potential to provide either direct or bridging therapy, and progressively broad definitions of oligometastasis.

Original languageEnglish (US)
Pages (from-to)8491-8524
Number of pages34
JournalOncotarget
Volume6
Issue number11
StatePublished - 2015

Fingerprint

Neoplasms
Molecular Pathology
Diagnostic Imaging
Therapeutics
Radiation
Neoplasm Metastasis

Keywords

  • Diaspora
  • Metastasis
  • Spectrum theory
  • Therapy
  • Tumor

ASJC Scopus subject areas

  • Oncology

Cite this

The biology and treatment of oligometastatic cancer. / Reyes, Diane K.; Pienta, Kenneth.

In: Oncotarget, Vol. 6, No. 11, 2015, p. 8491-8524.

Research output: Contribution to journalArticle

Reyes, DK & Pienta, K 2015, 'The biology and treatment of oligometastatic cancer', Oncotarget, vol. 6, no. 11, pp. 8491-8524.
Reyes, Diane K. ; Pienta, Kenneth. / The biology and treatment of oligometastatic cancer. In: Oncotarget. 2015 ; Vol. 6, No. 11. pp. 8491-8524.
@article{e66190e8577a46f588e64ea3b71e3ba4,
title = "The biology and treatment of oligometastatic cancer",
abstract = "Clinical reports of limited and treatable cancer metastases, a disease state that exists in a transitional zone between localized and widespread systemic disease, were noted on occasion historically and are now termed oligometastasis. The ramification of a diagnosis of oligometastasis is a change in treatment paradigm, i.e. if the primary cancer site (if still present) is controlled, or resected, and the metastatic sites are ablated (surgically or with radiation), a prolonged disease-free interval, and perhaps even cure, may be achieved. Contemporary molecular diagnostics are edging closer to being able to determine where an individual metastatic deposit is within the continuum of malignancy. Preclinical models are on the outset of laying the groundwork for understanding the oligometastatic state. Meanwhile, in the clinic, patients are increasingly being designated as having oligometastatic disease and being treated owing to improved diagnostic imaging, novel treatment options with the potential to provide either direct or bridging therapy, and progressively broad definitions of oligometastasis.",
keywords = "Diaspora, Metastasis, Spectrum theory, Therapy, Tumor",
author = "Reyes, {Diane K.} and Kenneth Pienta",
year = "2015",
language = "English (US)",
volume = "6",
pages = "8491--8524",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "11",

}

TY - JOUR

T1 - The biology and treatment of oligometastatic cancer

AU - Reyes, Diane K.

AU - Pienta, Kenneth

PY - 2015

Y1 - 2015

N2 - Clinical reports of limited and treatable cancer metastases, a disease state that exists in a transitional zone between localized and widespread systemic disease, were noted on occasion historically and are now termed oligometastasis. The ramification of a diagnosis of oligometastasis is a change in treatment paradigm, i.e. if the primary cancer site (if still present) is controlled, or resected, and the metastatic sites are ablated (surgically or with radiation), a prolonged disease-free interval, and perhaps even cure, may be achieved. Contemporary molecular diagnostics are edging closer to being able to determine where an individual metastatic deposit is within the continuum of malignancy. Preclinical models are on the outset of laying the groundwork for understanding the oligometastatic state. Meanwhile, in the clinic, patients are increasingly being designated as having oligometastatic disease and being treated owing to improved diagnostic imaging, novel treatment options with the potential to provide either direct or bridging therapy, and progressively broad definitions of oligometastasis.

AB - Clinical reports of limited and treatable cancer metastases, a disease state that exists in a transitional zone between localized and widespread systemic disease, were noted on occasion historically and are now termed oligometastasis. The ramification of a diagnosis of oligometastasis is a change in treatment paradigm, i.e. if the primary cancer site (if still present) is controlled, or resected, and the metastatic sites are ablated (surgically or with radiation), a prolonged disease-free interval, and perhaps even cure, may be achieved. Contemporary molecular diagnostics are edging closer to being able to determine where an individual metastatic deposit is within the continuum of malignancy. Preclinical models are on the outset of laying the groundwork for understanding the oligometastatic state. Meanwhile, in the clinic, patients are increasingly being designated as having oligometastatic disease and being treated owing to improved diagnostic imaging, novel treatment options with the potential to provide either direct or bridging therapy, and progressively broad definitions of oligometastasis.

KW - Diaspora

KW - Metastasis

KW - Spectrum theory

KW - Therapy

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=84928738955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928738955&partnerID=8YFLogxK

M3 - Article

C2 - 25940699

AN - SCOPUS:84928738955

VL - 6

SP - 8491

EP - 8524

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 11

ER -